VRCA - NASDAQ
Verrica Pharmaceuticals Inc.
$6.10
+6.7%Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
At a Glance
Live SnapshotVerrica Pharmaceuticals Inc. Management Team
Dr. Noah L. Rosenberg M.D.
Chief Medical Officer
Mr. David Zawitz
Chief Operating Officer
Mr. Eugene Scavola
Executive Vice President of Technical Operations
Dr. Bradley J. Catalone MBA, Ph.D.
Head of Drug Development
Mr. John J. Kirby CPA
Interim Chief Financial Officer
Dr. Jayson M. Rieger M.B.A., Ph.D.
President, Chief Executive Officer & Director
Compensation
$307,543
Verrica Pharmaceuticals Inc. Insider Positioning
During the last 12 months, insiders have purchased $10K worth of VRCA shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
2.4K
10.00K
0
0.00
+10K
+$10K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Rosenberg Noah L.
Officer: Cmo
$10K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $10K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
VRCA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 05, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 22, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 19, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 23, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 24, 2020 | June 11, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 25, 2019 | June 12, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.